3
Announcements
Trials
Browse
Landscape
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
8
Carcinoma, Non-Small-Cell Lung
4
Urinary Bladder Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Small Cell Lung Carcinoma
3
Liver Neoplasms
3
Stomach Neoplasms
2
Lung Neoplasms
2
Fallopian Tube Neoplasms
2
Carcinoma, Squamous Cell
2
Urothelial Cancer
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Unresectable Hepatocellular Carcinoma
1
Solid Malignancies
1
Seminoma
1
Prostatic Neoplasms
1
Peritoneal Neoplasms
1
Ovarian Neoplasms
1
Nonseminomatous germ cell tumor
1
Non Small Cell Lung Cancer NSCLC
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms
1
Neoplasm Metastasis
1
Microsatellite Instability
1
Metastatic Malignant Female Reproductive System Neoplasm
1
Mesothelioma, Malignant
1
Lung Cancer Metastatic
1
Immunotherapy
1
Hydronephrosis
1
Interventions
tremelimumab
1
durvalumab
1
atezolizumab
1
Bumetanide
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Unresectable Hepatocellular Carcinoma
×
tremelimumab
×
Clear all
NCT06117891
2026-05-12
REFINE-IO
Bayer
Active not recruiting
300 enrolled